Advaxia supports AAV, LVV, MVA, and oncolytic viruses through both standalone and integrated services, while end-to-end, integrated development and manufacturing support is available for adenovirus (AdV) programs.
ADVAXIA has a 100% GMP batch release track record and extensive experience delivering clinical lots under EMA, FDA, and MHRA standards, including for programs targeting HIV, Ebola, and COVID-19.
ADVAXIA offers a full suite of analytical, process development, and GMP manufacturing services for biologics and gene therapy products, as either stand-alone solutions, as part of an integrated project, or as a fully-managed program.
Our specialized services for adenoviral vectors span process development, analytical support, GMP manufacturing, and Fill & Finish — with built-in cold chain management and quality oversight throughout.
Scientific Director & Qualified Person
ADVAXIA BIOLOGICS
Project cooperation
Development of a novel vaccine for a viral pathogen
Production of batches of an Investigational Medicinal Product under GMP standard in the EU as a novel vaccine for a specific viral pathogen
Scientific Director & Qualified Person at ADVAXIA BIOLOGICS
Pomezia, Italy